Process for the synthesis of E1 activating enzyme inhibitors

US8933225B2 · kind B2 · utility

Assignee

• Millennium Pharmaceuticals, Inc. · US

Inventors

• Ian Armitage · Stoneham, US
• Eric L. Elliott · Watertown, US
• Marianne Langston · North Andover, US
• Steven P. Langston · North Andover, US
• Quentin J. McCubbin · Belmont, US
• Hirotake Mizutani · Cambridge, US
• Matthew Stirling · Boston, US
• Lei Zhu · Hefei, CN

Key dates

• Filing date: Aug 1, 2008
• Grant date: Jan 13, 2015
• Expiry date: Nov 21, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are processes and synthetic intermediates for the synthesis of compounds of formula (V) wherein the variables have the definitions contained herein. Such compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.